DLBCL Outcomes Vary Sharply for Patients 80 Years and Older

AJMC 16 April 2025 by Maggie Shaw

Patients who are 80 years and older who have diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma globally, require a higher level of attention and study of their disease and survival outcomes than is currently seen, explains new research in Cancer Epidemiology. Overall, patients in this age group comprise the fastest-growing age group in developed countries, the study’s authors explain, but because they are a heterogeneous group and few previous studies have investigated variances in their characteristics, care management, and survival outcomes, more attention must be paid.

Data from the Real-World Data in Lymphoma and Survival in Adults study (REALYSA; NCT03869619) were used for this analysis. All of the patients included were older than 60 years (60-69 years, n = 233; 70-79 years, n = 246; 80 years or older, n = 81), had no prior history of lymphoma, had newly diagnosed DLBCL, and received treatment a between November 2018 and December 2021 at 23 of the 35 hematology departments across France that participated in REALYSA and collected epidemiological data. That treatment was either rituximab/cyclophosphamide/doxorubicin hydorchloride/vincristine (Oncovin)/prednisone (R-CHOP), mini R-CHOP (reduced-dose R-CHOP), or another treatment. The primary outcome of interest for the REALYSA study is progression-free survival (PFS) at 5 years, and secondary outcomes of interest include measures at 5 years and 9 years for PFS, overall survival, event-free survival, duration of response, and frequency of second cancers.

Link to full article : https://www.ajmc.com/view/dlbcl-outcomes-vary-sharply-for-patients-80-years-and-older